← Eichor
Study identifier: NCT06554288 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Condition: Pediatric Disorder · Genetic Predisposition · Dystonia, Secondary  ·  Sponsor: Children's Mercy Hospital Kansas City

PhasePhase 1
Planned participants40
Who can joinAll sexes, 5 Years to 17 Years
Healthy volunteersNo

About this study

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

This description comes directly from the study's public registry record.

Talk to the study team

Rose Gelineau-Morel, MD  ·  816-302-3331  ·  rngelineaumorel@cmh.edu

Rachel Nass  ·  8166011354  ·  rnass@cmh.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Children's Mercy Hospital Kansas CityKansas City, Missouri, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06554288